AIM: To evaluate the efficacy of rituximab combined with cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) in treating the initially diagnosed diffuse large B cell lymphoma (DLBL). METHODS: From Apr.20...AIM: To evaluate the efficacy of rituximab combined with cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) in treating the initially diagnosed diffuse large B cell lymphoma (DLBL). METHODS: From Apr.2002 to Feb. 2003, 52 patients were enrolled in this study. Chemotherapy was conducted with cyclophosphamide 600 mg·m^-2, vincristine 1.4 mg·m^-2,doorubicin 25mg·m^-2 on d 1 and prednisone 60 mg·d^-l for successive 5 d (standard CHOP). There were 6 courses, 3 wk each. Rituximab 375 mg·m^-2 was infused once a week, 2 d before the first course of chemotherapy (successive infusion) for 4 times on standard dose or for 6 times on extended dose. Or rituximab was infused once every 3 wk, 2 d before each CHOP (separated infusion) for 4 times on the schedule of standard dose or for 6 times on the extended dose. RESULTS: The complete response (CR) rate (60%) and total effective (100%) were achieved in 50 patients who were evaluated for efficacy, respectively. And among 34 patients in Ann Arbor stage Ⅲ and Ⅳ, 15 patients were completely relieved. The complete effective rate was 44%. Fifty patients were followed-up for (8±s 5) wk, 2-30wk and estimated progress free survival (PFS) rate of 16 wk was 87 %. Standard and extend regimen were not different in effect, as well as the separated or concentrated infusion of rituximab (P>0.05). The regimen could be well tolerated, and the major adverse reactions were infusion-related response (32 % ) and hematological toxicities (20 %). CONCLUSION:Rituximab in combined with CHOP can be successfully applied to the therapy of initially diagnosed diffuse large B cell lymphoma, with high CR rate and mild adverse reactions.展开更多
文摘AIM: To evaluate the efficacy of rituximab combined with cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) in treating the initially diagnosed diffuse large B cell lymphoma (DLBL). METHODS: From Apr.2002 to Feb. 2003, 52 patients were enrolled in this study. Chemotherapy was conducted with cyclophosphamide 600 mg·m^-2, vincristine 1.4 mg·m^-2,doorubicin 25mg·m^-2 on d 1 and prednisone 60 mg·d^-l for successive 5 d (standard CHOP). There were 6 courses, 3 wk each. Rituximab 375 mg·m^-2 was infused once a week, 2 d before the first course of chemotherapy (successive infusion) for 4 times on standard dose or for 6 times on extended dose. Or rituximab was infused once every 3 wk, 2 d before each CHOP (separated infusion) for 4 times on the schedule of standard dose or for 6 times on the extended dose. RESULTS: The complete response (CR) rate (60%) and total effective (100%) were achieved in 50 patients who were evaluated for efficacy, respectively. And among 34 patients in Ann Arbor stage Ⅲ and Ⅳ, 15 patients were completely relieved. The complete effective rate was 44%. Fifty patients were followed-up for (8±s 5) wk, 2-30wk and estimated progress free survival (PFS) rate of 16 wk was 87 %. Standard and extend regimen were not different in effect, as well as the separated or concentrated infusion of rituximab (P>0.05). The regimen could be well tolerated, and the major adverse reactions were infusion-related response (32 % ) and hematological toxicities (20 %). CONCLUSION:Rituximab in combined with CHOP can be successfully applied to the therapy of initially diagnosed diffuse large B cell lymphoma, with high CR rate and mild adverse reactions.
